Vozikis Athanassios, Cooper David N, Mitropoulou Christina, Kambouris Manousos E, Brand Angela, Dolzan Vita, Fortina Paolo, Innocenti Federico, Lee Ming Ta Michael, Leyens Lada, Macek Milan, Al-Mulla Fahd, Prainsack Barbara, Squassina Alessio, Taruscio Domenica, van Schaik Ron H, Vayena Effy, Williams Marc S, Patrinos George P
Laboratory of Health Economics and Management, Department of Economics, University of Piraeus, Piraeus, Greece.
Public Health Genomics. 2016;19(6):352-363. doi: 10.1159/000449152. Epub 2016 Sep 28.
This paper aims to provide an overview of the rationale and basic principles guiding the governance of genomic testing services, to clarify their objectives, and allocate and define responsibilities among stakeholders in a health-care system, with a special focus on the EU countries. Particular attention is paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differs between various countries owing to differences in disease prevalence and public health relevance, the prescribing and use of genomic testing services according to existing or new guidelines, budgetary and fiscal control, the balance between price and access to innovative testing, monitoring and evaluation for cost-effectiveness and safety, and the development of research capacity. We conclude that addressing the specific items put forward in this article will help to create a robust policy in relation to pricing and reimbursement in genomic medicine. This will contribute to an effective and sustainable health-care system and will prove beneficial to the economy at large.
本文旨在概述指导基因组检测服务管理的基本原理和原则，阐明其目标，并在医疗保健系统中的利益相关者之间分配和界定责任，特别关注欧盟国家。尤其关注与定价和报销政策、由于疾病流行率和公共卫生相关性不同而在各国之间存在差异的基本基因组检测的可及性、根据现有或新指南开具和使用基因组检测服务、预算和财政控制、价格与创新检测可及性之间的平衡、成本效益和安全性的监测与评估，以及研究能力的发展等相关问题。我们得出结论，解决本文提出的具体问题将有助于制定关于基因组医学定价和报销的稳健政策。这将有助于建立一个有效且可持续的医疗保健系统，并将对整个经济产生益处。
